An increasing number of clinical studies highlight the importance of the inflammatory mediator prostaglandin F 2a (PGF 2a ). Prostaglandin F 2a activity has been suggested to play pivotal roles in the development of cardiovascular diseases and cancer. However, whether systemic PGF 2a concentrations may signal mortality is unknown. The aim was to evaluate in vivo PGF 2a formation, by measuring urinary 15-keto-dihydro-PGF 2a , and mortality risk in a community setting.
Introduction
Cytokines and cytokine-induced acute phase proteins are signalling molecules related to inflammation and inflammation-related pathology. Several epidemiological studies have shown that increased concentrations of these cytokines or cytokine-induced proteins in the circulation may predict cardiovascular disease (CVD), cancer, and mortality. 1 -7 On the other hand, mediators that exert the critical bioactive effects in the initiation of inflammatory processes have been far less determined and evaluated in clinical epidemiological studies.
The cyclooxygenase-mediated prostaglandins (PGs), thromboxanes, and prostacyclins are classical examples of bioactive mediators with potent vasoconstrictive/vasodilatory and inflammatory properties exerting direct well-known effects on the endothelium and homoeostasis. 8, 9 Until recently, PGs have rarely been studied in large community settings, possibly due to their short half-life and subsequent difficulties in the methodology of large-scale measurements of relatively minute amounts in biological samples (basal concentrations 2 pg/mL in plasma). Prostaglandin F 2a (PGF 2a ) is one of the major stable PGs formed during both acute and chronic inflammation and is found locally and systemically. 10 -12 Owing to the risk of artefactual formation during sample collection and the short half-life of PGF 2a ( 1 min) 19 and studies are now emerging suggesting that PGF 2a, in particular, may be of importance for CVD development. 12 Moreover, several lines of evidence suggest a causal role for PGs, and possibly PGF 2a , in the complex pathophysiology leading to cancer.
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Based on previous studies supporting a link between PGs and the development of CVD and cancer, we hypothesized that enhanced formation of the inflammatory mediator PGF 2a may potentially indicate increased mortality risk. The aim of this study was therefore to explore the associations between urinary concentrations of 15-keto-dihydro-PGF 2a and the risk of cardiovascular, cancer and total death in a community-based cohort of elderly men with up to 12 years of follow-up.
Methods

Study population
The Swedish cohort Uppsala Longitudinal Study of Adult Men was initiated in 1970 when all 50-year-old men living in Uppsala county (n ¼ 2841) were invited to participate in a health survey (participation rate 82%). 27 Participants from the third re-investigation of the cohort, performed during 1997 -2001 at 77 -78 years of age, were included in this study. Of the 839 participants, 133 were excluded because of absent urinary collection and 36 because of missing data on covariates; thus 670 men constituted the study population. The study complies with the Declaration of Helsinki and the Ethics Committee at Uppsala University approved the study; all participants gave their informed consent.
Baseline investigations
Twenty-four hour urine specimens were collected, aliquoted, and stored at 2708 until analysis. Urinary 15-keto-dihydro-PGF 2a concentrations were determined using a radioimmunoassay developed as previously described by Basu. 17 The intra-assay coefficient of variation was 
Endpoint definitions
The Swedish Cause of Death register was used to define the endpoints cardiovascular mortality (ICD-10 I00-99), cancer mortality (ICD-10 C00-D48), and total mortality.
Statistics
The associations of urinary 15-keto-dihydro-PGF 2a concentrations and cardiovascular, cancer, and total mortality, respectively, were analysed with Cox proportional hazard regression in a univariable and in three multivariable models (A, B, and C). In primary models urinary 15-keto-dihydro-PGF 2a was entered as a standardized continous variable (1 SD increase) and in secondary models as a binary variable (above/below median). To construct thrifty statistical multivariate models, we used the directed acyclic graph (DAG) tool software available on http://dagitty.net. 31 DAGitty is a graphical and mathematical tool for analysing causal diagrams to optimize the choice of covariates in the multivariate models and thus minimize the bias of the effect estimates and maintain as many degrees of freedom as possible. Possible confounding factors (low-dose aspirin, lipid-lowering and anti-hypertensive treatment, age, systolic blood pressure, body mass index, total cholesterol, high-density lipoprotein cholesterol, triglycerides, smoking status, diabetes, eGFR cysC , education level, physical activity, and prevalent CVD) were entered into the DAG tool. Covariates for the large models B and C were chosen according to the results of the DAG. Model A was adjusted for low-dose aspirin treatment (75 -160 mg salicylic acid daily) due to the known direct therapeutic cyclooxygenase-inhibitor effect of salicylic acid on PG synthesis. 32, 33 Model B was adjusted for low-dose aspirin treatment and established cardiovascular risk factors including systolic blood pressure, body mass index, smoking status, diabetes, eGFR cysC , and prevalent CVD. Model C was adjusted for the same as model B and additionally for C-reactive protein. Non-linear trends of mortality risk were analysed using a restricted cubic spline Cox regression model with four degrees of freedom. The knots were set at the 10th, 50th, and 90th percentiles, corresponding to urinary 15-keto-dihydro-PGF 2a at 0.168, 0.282, and 0.503 ng/mmol Cr. To evaluate the interplay between urinary 15-keto-dihydro-PGF 2a and serum C-reactive protein in risk estimation of cardiovascular, cancer, and total mortality, we divided the participants in four groups: (i) low urinary 15-keto-dihydro-PGF 2a and low C-reactive protein, (ii) high urinary 15-keto-dihydro-PGF 2a and low C-reactive protein, (iii) low urinary 15-keto-dihydro-PGF 2a and high C-reactive protein, (iv) high urinary 15-keto-dihydro-PGF 2a and high C-reactive protein. Low urinary 15-keto-dihydro-PGF 2a is defined as ≤0.28 nmol/mmol Cr (below median) and high urinary 15-keto-dihydro-PGF 2a as .0.28 nmol/mmol Cr. Low C-reactive protein is defined as ≤3 mg/L and high C-reactive protein as .3 mg/L according to the risk classification guidelines for CVD by American Heart Association. 34 We performed tests for effect modification by prevalent CVD, diabetes, smoking, low-dose aspirin treatment, and C-reactive protein by including multiplicative interaction terms of these variables and urinary 15-keto-dihydro-PGF 2a . Two-sided P-values ,0.05 were regarded as statistically significant. Calculations and graphs were performed with Stata 11.0 (College Station, TX, USA).
Results
Baseline characteristics of the study population are shown in Table 1 . The participants were followed up for a median of 9.7 years (interval 0.3 -12.8 years). The mortality incidence rates for urinary 15-keto-dihydro-PGF 2a are shown in Table 2 .
Cardiovascular mortality
One SD increase of urinary 15-keto-dihydro-PGF 2a was significantly associated with an increased HR of cardiovascular mortality in the univariable model and in the models adjusting for low-dose aspirin treatment and established cardiovascular risk factors including C-reactive protein, respectively ( Table 2 ). The regression spline suggested a linear increase in hazard for total mortality with increasing urinary 15-keto-dihydro-PGF 2a ( Figure 1 ). Participants with a urinary 15-keto-dihydro-PGF 2a above the median were borderline significantly (P ¼ 0.05) associated with an increased HR of cardiovascular mortality in the model adjusting for low-dose aspirin treatment. The cumulative incidence of cardiovascular mortality in urinary 15-keto-dihydro-PGF 2a above the median vs. below the median is shown in Figure 2 . Participants with a combination of high urinary 15-keto-dihydro-PGF 2a and high C-reactive protein had a significant two-fold increased risk of cardiovascular mortality compared with participants with low urinary 15-keto-dihydro-PGF 2a and low C-reactive protein (Table 3) . However, this association was only borderline significant when cardiovascular risk factors were adjusted for.
No effect modification of prevalent CVD (P ¼ 0.91), diabetes (P ¼ 0.49), smoking (P ¼ 0.41), low-dose aspirin treatment (P ¼ 0.32), or C-reactive protein (P ¼ 0.70) was observed for the associations between urinary 15-keto-dihydro-PGF 2a and cardiovascular mortality.
Cancer mortality
We did not find any significant association between urinary 15-keto-dihydro-PGF 2a and risk of cancer mortality in the continuous models or the categorical models ( Table 2) . However, participants with a combination of high urinary 15-keto-dihydro-PGF 2a and high C-reactive protein had a significant two-fold increased risk of cancer mortality compared with participants with low urinary 15-keto-dihydro-PGF 2a and low C-reactive protein concentrations ( Table 3 ). This association did not substantially change after adjustment for cardiovascular risk factors.
Total mortality
A 1 SD increase of urinary 15-keto-dihydro-PGF 2a was significantly associated with an increased hazard ratio (HR) of total mortality in the univariable model and in the models adjusting for low-dose aspirin treatment and established cardiovascular risk factors including C-reactive protein, respectively ( Table 2) . Participants with a urinary 15-keto-dihydro-PGF 2a concentration above the median were also significantly associated with an increased HR of total mortality in the univariable model and in all multivariable models adjusting for cardiovascular risk factors including C-reactive protein ( Table 2) Participants with a combination of high urinary 15-keto-dihydro-PGF 2a and high C-reactive protein concentrations had a highly significant two-fold increased risk of total mortality compared with participants with low urinary 15-keto-dihydro-PGF 2a and low C-reactive protein concentrations ( Table 3) . This association did not substantially change when adjusting for cardiovascular risk factors.
No effect modification of prevalent CVD (P ¼ 0.94), diabetes (P ¼ 0.91), smoking (P ¼ 0.93), low-dose aspirin treatment (P ¼ 0.46), or C-reactive protein (P ¼ 0.36) was observed for the associations between urinary 15-keto-dihydro-PGF 2a and total mortality.
Discussion
This is the first study to explore the associations between the inflammatory mediator PGF 2a and mortality in a community setting, and it shows that PGF 2a formation in older men is associated with cardiovascular and total mortality up to 12 years later. The associations could primarily not be explained by any other common cardiovascular risk factor, indicating that PGF 2a may add important additional information on detrimental cardiovascular risk. The physiological role of PGF 2a is well known in the field of reproductive endocrinology 12 where it has essential mediator roles during luteolysis, ovulation, sperm transportation, pregnancy establishment, cervix dilation, and parturition in humans and different animal species. 35 -38 41 and low intake of vitamins. 40 Further, increased intima-media thickness in the carotid artery, corresponding to enhanced total atherosclerotic load in the artery system, is independently associated with increased urinary 15-keto-dihydro-PGF 2a concentrations. 44 These studies may all together indicate a possible role for the inflammatory, vasoconstrictive mediator PGF 2a as an important factor related to atherogenesis and subsequently cardiovascular mortality. The independent associations between 15-keto-dihydro-PGF 2a and cardiovascular mortality found in this study further confirms this hypothesis.
The associations between urinary 15-keto-dihydro-PGF 2a and cardiovascular mortality could primarily not be explained by highsensitive C-reactive protein, according to the multivariate analyses. Speculatively, the results may indicate that C-reactive protein and 15-keto-dihydro-PGF 2a measurements in part reflect different . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ ......   .... ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ . ..... Table 3 The combined effects of urinary 15-keto-dihydro-prostaglandin F 2a and serum C-reactive protein for cardiovascular, cancer, and total mortality risk estimated by Cox regression models aspects of inflammation. C-reactive protein is primarily an acute phase protein synthesized in the liver by the signal of activated proinflammatory cytokines. There is an unclear consensus whether C-reactive protein represents a cardiovascular risk factor with bioactive properties related to atherogenesis or rather a risk marker of general chronic inflammation. 34 Despite this, C-reactive protein is currently shown to be an important and consistent predictor of cardiovascular morbidity and mortality, especially in middle-aged subjects. For older age groups, however, the predictive value of C-reactive protein is far less studied, and evaluated clinical studies have shown inconsistent outcomes. 4 Prostaglandin F 2a , on the other hand, has well-known potent bioactivity by primarily being a vasoconstrictor at sites of inflammation 10 -12 and is essentially inhibited by aspirin and other non-steroidal anti-inflammatory drugs. This study also showed that urinary 15-keto-dihydro-PGF 2a was independently associated with total mortality, representing a heterogeneous endpoint. One interpretation may be that this association is in part driven by the association between urinary 15-keto-dihydro-PGF 2a and CVD mortality since CVD is a major cause of death in this age group. Another interpretation may speculatively be that increased urinary 15-keto-dihydro-PGF 2a concentrations signal a state of increased inflammation and vasoconstriction which may be important in the pathogenesis leading to death by different causes, including accelerating atherosclerosis as discussed above, functional decline, or other crucial morbidity. Studies have shown that other inflammatory biomarkers in settings of very old adults may represent age-related functional decline in general, 46 or other chronic conditions possibly related to mortality. 4 The strengths of this study include the community-based study design, which to our knowledge is the only community cohort with estimations of urinary 15-keto-dihydro-PGF 2a . In addition, this study has also detailed clinical and biochemical characterization of cardiovascular risk factors including C-reactive protein measurements. The study is longitudinal with a relatively long follow-up time and a very low loss to follow-up due to the high-quality Swedish registry data. However, the problems of generalizing these results to women, other age groups, and other ethnic groups have to be acknowledged. Further, the results may be related to or depend on variables that we were unable to adjust for. It cannot be ruled out that the results of this study to some extent are related to reverse causation; that is, high urinary 15-keto-dihydro-PGF 2a is rather a consequence of prevalent disease with related low-grade inflammation at baseline.
Conclusion
This is the first study to show that formation and excretion of the inflammatory mediator PGF 2a were independently associated with mortality and specifically cardiovascular mortality 10 years later. The results are in line with the emerging evidence of the importance of PGF 2a as a cardiovascular risk factor and suggest that PGF 2a may carry risk information beyond the established cardiovascular risk factors. However, the clinical utility of measuring urinary 15-ketodihydro-PGF 2a for risk prediction purposes needs to be further evaluated.
